In vivo evaluation of mebendazole and Ran GTPase inhibition in breast cancer model system. (2024)

Peer-Reviewed Study · Balqis Abu-Hdaib; Hamdi Nsairat; Mohamed El-Tanani et al. · 2024

Balqis Abu-Hdaib et al., 2024: Study of a mebendazole-loaded nanostructured lipid carrier in a breast cancer mouse model, reporting smaller tumours and fewer lung metastases than free drug.

NLC-MBZ decreased tumor size, suppressed tumor lung metastases, and lowered the expression of CDC25A, SKP2, RbX1 and Cullin1 while boosting the Rb proteins.

Balqis Abu-Hdaib et al., 2024: Study of a mebendazole-loaded nanostructured lipid carrier in a breast cancer mouse model, reporting smaller tumours and fewer lung metastases than free drug. Study type: MDA-MB-231 cells plus in vivo breast cancer model. N: not stated in the abstract. Country: Jordan (Al-Ahliyya Amman University). Dose: free MBZ IC50 610 nM and NLC-MBZ 305 nM in vitro; in vivo dose not stated in the abstract. Funder: not stated in the record. Declared conflicts: 'The authors have no competing interests…'. Comparator: free mebendazole and vehicle. Note this is a formulation study: the active comparison is carrier versus free drug. Study type: animal.